Early Assessment of Treatment Response Using Functional Diffusion Mapping

Completed · Not applicable

Conditions studied: Prostate Cancer

In brief

This study will evaluate the feasibility of identifying changes in diffusion MRI characteristics of bone that correlates with response to therapy in men with metastatic prostate cancer.

Key facts

Study ID

NCT02064283

Run by

University of Michigan Rogel Cancer Center

People needed

20

Starts

2007-05-01

Expected to finish

2012-10-01

Last updated by the study team

2014-12-09

Who can join

Age: any. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of prostate cancer.
• Evidence of metastatic disease by bone scan.
• Patients must be initiating systemic therapy for metastatic disease.
• New D2 disease beginning therapy with androgen deprivation.
• CRPC (Castration Resistant Prostate Cancer) beginning systemic non hormonal therapy.
• Patients must be willing to provide the blood samples for the correlative markers.
• Patients must be able to lie flat in an MRI (Magnetic Resonance Imaging) magnet for 30-60 minutes.
• Life expectancy of 12 weeks or greater.
• All patients must be informed of the investigational nature of this study and must sign an informed consent in accordance with institutional and federal guidelines.

You may not qualify if…

• Contraindication to MRI imaging.
• Patients who require sedation with general anesthesia to undergo MRI imaging.
• Weight greater than 275 pounds.

Where it is running

• The University of Michigan Comprehensive Cancer Center — Ann Arbor, Michigan, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.